Exelixis
EXEL
#1829
Rank
S$14.86 B
Marketcap
S$57.23
Share price
3.19%
Change (1 day)
23.21%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): S$3.74

According to Exelixis's latest financial reports the company's current EPS (TTM) is S$3.68. In 2023 the company made an earnings per share (EPS) of S$0.83 an increase over its 2022 EPS that were of S$0.72.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$3.74
2023S$0.8314.61%
2022S$0.72-22.97%
2021S$0.94100%
2020S$0.47-65.09%
2019S$1.35-53.91%
2018S$2.92333.96%
2017S$0.67-260.61%
2016S-$0.42-58.75%
2015S-$1.02-42.45%
2014S-$1.775.3%
2013S-$1.68

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
S$14.17 285.42%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$1.73-52.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
S$18.22 395.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
S$2.63-28.54%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
S$9.30 152.95%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$4.40 19.72%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
S$4.79 30.38%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
S-$4.67-226.99%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
S-$1.07-129.07%๐Ÿ‡บ๐Ÿ‡ธ USA